During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...

Efficacy findings from the phase 2 AGAVE-201 support the use of axatilimab, which was approved by the FDA for recurrent or ...

During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

During a Case-Based Roundtable® event, Virginia F. Borges, MD, MMSc, discussed treatment selection for a patient with ER+, ...

NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

Anil Parwani, MD, PhD, discusses the challenges and opportunities he has encountered in either implementing or utilizing ...

During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with chronic lymphocytic ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or ...

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented ...